SCHEMBL12645679

SCHEMBL12645679

Cc1c(Nc2cccc(Cl)c2)nc2c(/C=C3\NC(=O)NC3=O)cnn2c1NC1CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2B P67870 4/20 0.45
CDK1 P06493 4/20 0.38
PRKCA P17252 1/20 0.36
PDGFRA P16234 4/20 0.36
CCNE1 P24864 4/20 0.36
CDK2 P24941 4/20 0.36
HPGD P15428 3/20 0.35
ALDH1A1 P00352 2/20 0.35
CNR2 P34972 1/20 0.35
KDM4E B2RXH2 4/20 0.35
PKM P14618 1/20 0.35
MAPK1 P28482 2/20 0.34
MEN1 O00255 1/20 0.34
CYP1A2 P05177 1/20 0.34
POLB P06746 1/20 0.34
HSP90AA1 P07900 1/20 0.34
CYP3A4 P08684 1/20 0.34
MAPT P10636 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19526993 0.86 CSNK2B (0.34) CSNK2BCDK1CDK2HPGDALDH1A1
SCHEMBL14242880 0.85 CSNK2B (0.37) CSNK2BCDK1CDK2HPGDALDH1A1
SCHEMBL2029600 0.83 CSNK2A1 (0.47) CSNK2BCDK1PRKCAHPGDKDM4E
SCHEMBL2031096 0.83 CSNK2B (0.47) CSNK2BCSNK2A2CSNK2A1
SCHEMBL2031097 0.83 CSNK2B (0.47) CSNK2BCSNK2A2CSNK2A1
SCHEMBL2029597 0.83 CSNK2A1 (0.47) CSNK2BCDK1PRKCAHPGDKDM4E
SCHEMBL12583206 0.83 CSNK2B (0.47) CSNK2BCSNK2A2CSNK2A1
SCHEMBL2029594 0.83 CSNK2A1 (0.47) CSNK2BCDK1PRKCAHPGDKDM4E
SCHEMBL1487847 0.82 KDM4E (0.38) CSNK2BCDK2ALDH1A1KDM4EMAPK1
SCHEMBL1487845 0.82 KDM4E (0.38) CSNK2BCDK2ALDH1A1KDM4EMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9303033-B2 Pyrazolopyrimidines and related heterocycles as CK2 inhibitors SENHWA BIOSCIENCES, INC. (TW) 2016-04-05 US disclosed
US-8575177-B2 Pyrazolopyrimidines and related heterocycles as CK2 inhibitors SENHWA BIOSCIENCES, INC. (TW) 2013-11-05 US disclosed
US-20110152240-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS CYLENE PHARMACEUTICALS, INC. (US) 2011-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110152240-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS CDK2, CKS2, CSNK2A1 CSNK2B 13/4885CDK1 11/4885PRKCA 126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.